Risk factors for vertebral fractures and bone loss after denosumab discontinuation: A real-world observational study

A Single Infusion of Zoledronate in Postmenopausal Women Following Denosumab Discontinuation Results in Partial Conservation of Bone Mass Gains

(2020) Judith Everts‐Graber et al.   JOURNAL OF BONE AND MINERAL RESEARCH

Delayed Denosumab Injections and Bone Mineral Density Response: An Electronic Health Record-based Study

(2020) Houchen Lyu et al.   JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM

Zoledronate Following Denosumab Discontinuation: Partial Reassurance but No Confidence

(2020) Serge Ferrari   JOURNAL OF BONE AND MINERAL RESEARCH

Treatment with zoledronate subsequent to denosumab in osteoporosis: a randomized trial

(2020) Anne Sophie Sølling et al.   JOURNAL OF BONE AND MINERAL RESEARCH

The three-year effect of a single zoledronate infusion on bone mineral density and bone turnover markers following denosumab discontinuation in women with postmenopausal osteoporosis

(2020) Polyzois Makras et al.   BONE

Alendronate after denosumab discontinuation in women previously exposed to bisphosphonates was not effective in preventing the risk of spontaneous multiple vertebral fractures: two case reports

(2019) O. Lamy et al.   OSTEOPOROSIS INTERNATIONAL

Stopping Denosumab

(2019) Olivier Lamy et al.   Current Osteoporosis Reports

Effect of Zoledronate on Bone Loss After Romosozumab/Denosumab: 2-Year Follow-up

(2019) Anne M. Horne et al.   CALCIFIED TISSUE INTERNATIONAL

Zoledronate for the Prevention of Bone Loss in Women Discontinuing Denosumab Treatment. A Prospective 2‐year Clinical Trial

(2019) Athanasios D. Anastasilakis et al.   JOURNAL OF BONE AND MINERAL RESEARCH

Bone Mineral Density After Transitioning From Denosumab to Alendronate

(2019) David Kendler et al.   JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM

Fracture incidence after denosumab discontinuation: Real-world data from a large healthcare provider

(2019) Liana Tripto-Shkolnik et al.   BONE

Bone Loss After Romosozumab/Denosumab: Effects of Bisphosphonates

(2018) Anne M. Horne et al.   CALCIFIED TISSUE INTERNATIONAL

Denosumab versus risedronate in glucocorticoid-induced osteoporosis: a multicentre, randomised, double-blind, active-controlled, double-dummy, non-inferiority study

(2018) Kenneth G Saag et al.   Lancet Diabetes & Endocrinology

New and emerging concepts in the use of denosumab for the treatment of osteoporosis

(2018) E. Michael Lewiecki   Therapeutic Advances in Musculoskeletal Disease

Vertebral Fractures After Discontinuation of Denosumab: A Post Hoc Analysis of the Randomized Placebo-Controlled FREEDOM Trial and Its Extension

(2017) Steven R Cummings et al.   JOURNAL OF BONE AND MINERAL RESEARCH

Clinical Features of 24 Patients With Rebound-Associated Vertebral Fractures After Denosumab Discontinuation: Systematic Review and Additional Cases

(2017) Athanasios D Anastasilakis et al.   JOURNAL OF BONE AND MINERAL RESEARCH

Retrospective evaluation of serum CTX levels after denosumab discontinuation in patients with or without prior exposure to bisphosphonates

(2017) B. Uebelhart et al.   OSTEOPOROSIS INTERNATIONAL

Possible protective effect of switching from denosumab to zoledronic acid on vertebral fractures

(2017) T. Lehmann et al.   OSTEOPOROSIS INTERNATIONAL

Observations following discontinuation of long-term denosumab therapy

(2017) M. R. McClung et al.   OSTEOPOROSIS INTERNATIONAL

Osteoporosis drug treatment: duration and management after discontinuation. A position statement from the SVGO/ASCO

(2017)   SWISS MEDICAL WEEKLY

10 years of denosumab treatment in postmenopausal women with osteoporosis: results from the phase 3 randomised FREEDOM trial and open-label extension

(2017) Henry G Bone et al.   Lancet Diabetes & Endocrinology

UK clinical guideline for the prevention and treatment of osteoporosis

(2017) J. Compston et al.   Archives of Osteoporosis

Adjuvant denosumab in breast cancer (ABCSG-18): a multicentre, randomised, double-blind, placebo-controlled trial

(2015) Michael Gnant et al.   LANCET

Severe spontaneous vertebral fractures after denosumab discontinuation: three case reports

(2015) B. Aubry-Rozier et al.   OSTEOPOROSIS INTERNATIONAL

Multiple clinical vertebral fractures following denosumab discontinuation

(2015) A. D. Anastasilakis et al.   OSTEOPOROSIS INTERNATIONAL

The effect of 8 or 5 years of denosumab treatment in postmenopausal women with osteoporosis: results from the FREEDOM Extension study

(2015) S. Papapoulos et al.   OSTEOPOROSIS INTERNATIONAL

The Effect of Three or Six Years of Denosumab Exposure in Women With Postmenopausal Osteoporosis: Results From the FREEDOM Extension

(2013) Henry G. Bone et al.   JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM

Five years of denosumab exposure in women with postmenopausal osteoporosis: Results from the first two years of the FREEDOM extension

(2011) Socrates Papapoulos et al.   JOURNAL OF BONE AND MINERAL RESEARCH

Effects of Denosumab Treatment and Discontinuation on Bone Mineral Density and Bone Turnover Markers in Postmenopausal Women with Low Bone Mass

(2011) Henry G. Bone et al.   JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM

Denosumab for Prevention of Fractures in Postmenopausal Women with Osteoporosis

(2009) Steven R. Cummings et al.   NEW ENGLAND JOURNAL OF MEDICINE

Effect of denosumab on bone density and turnover in postmenopausal women with low bone mass after long-term continued, discontinued, and restarting of therapy: A randomized blinded phase 2 clinical trial

(2008) Paul D. Miller et al.   BONE